Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Reports First Quarter 2019 Financial Results
Projected cash runway extended to first quarter 2020 SOLANA BEACH, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter
View HTML
Toggle Summary Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA
SOLANA BEACH, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S.
View HTML
Toggle Summary Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA
Meeting with FDA scheduled for March 21, 2019 SOLANA BEACH, Calif. , March 14, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted its response to the U.S.
View HTML
Toggle Summary Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication
Recently received multi-disciplinary review (DR) letter from U.S. Food and Drug Administration ( FDA ) for Gimoti™ 505(b)(2) New Drug Application (NDA) April 1 , 2019 Prescription Drug User Fee Act (PDUFA) date maintained Company expects to hold a conference call at a later date instead of its
View HTML
Toggle Summary Evoke Pharma Receives Preliminary FDA Communication on Gimoti™ NDA
SOLANA BEACH Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), today announced the receipt of a multi-disciplinary review (DR) letter from the U.S. Food and Drug Administration ( FDA ) in association with the Gimoti 505(b)(2) New Drug Application (NDA).
View HTML
Toggle Summary Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results
SOLANA BEACH, Calif. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company will release financial results for the fourth quarter and full year ended
View HTML
Toggle Summary Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners
Novos to provide fully integrated commercial function for Evoke and non-dilutive financing for the commercialization of Gimoti, extending cash runway into 2020 Evoke will retain greater than 80% of product profits following approval SOLANA BEACH, Calif. , Jan.
View HTML
Toggle Summary Evoke Pharma Reports Third Quarter 2018 Results
April 1, 2019 PDUFA date for Gimoti™ NDA Cash runway extended through June 2019 SOLANA BEACH, Calif. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial
View HTML
Toggle Summary Evoke Pharma’s Gimoti™ NDA Accepted for FDA Review
April 1, 2019 PDUFA Target Goal Date Gimoti Brand Name Conditionally Accepted SOLANA BEACH, Calif. , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company’s
View HTML
Toggle Summary Evoke Pharma Reports Second Quarter 2018 Results and Recent Highlights
Gimoti ™ NDA submitted to FDA on June 1 st ; awaiting 74-Day FDA filing communication letter Gender-specific patents granted for Gimoti in the European Union and Mexico SOLANA BEACH, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company
View HTML